CYCN - Cyclerion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Cyclerion Therapeutics, Inc.

301 Binney Street
Cambridge, MA 02142
United States

Full Time Employees140

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter M. HechtCEO & DirectorN/AN/A1964
Dr. Mark G. CurriePres & Chief Scientific OfficerN/AN/A1955
Mr. William HuyettChief Financial OfficerN/AN/A1956
Mr. Brian M. CaliHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Lawrence MillerGen. CounselN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its lead product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of serious cardiometabolic diseases, such as diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for serious and orphan central nervous system diseases. The company's products that are in discovery stage include liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.

Corporate Governance

Cyclerion Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.